Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).

Abstract excerpt

INTRODUCTION: Leucine-rich repeat kinase 2 (LRRK2) has received considerable attention since the discovery of LRRK2 mutations in families with dominantly inherited Parkinson's disease (PD) in 2004. The missense mutation G2019S is the most common LRRK2 mutation and has been identified in both familial and sporadic PD cases. The G2019S mutation enhances kinase activity suggesting that LRRK2 could be an attractive...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antiparkinson Agents
• Share to Drug Design
• Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2